Latest ThromboGenics NV Stories
LEUVEN, Belgium, March 10, 2014 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing
LEUVEN, Belgium, March 4, 2014 /PRNewswire/ -- Ocriplasmin Research to Better Inform Treatment (ORBIT) study designed to generate further
LEUVEN, Belgium, February 24, 2014 /PRNewswire/ -- Focus on Realizing the Commercial Potential of JETREA(R)in the US and Capitalizing on the
- A volcanic mudflow.